Davis R L, Quenzer R W, Bozigian H P, Warner C W
College of Pharmacy, University of New Mexico, Albuquerque 87131.
DICP. 1990 Nov;24(11):1040-3. doi: 10.1177/106002809002401101.
The pharmacokinetics of a single dose of ranitidine 50 mg iv were determined in ten normal-weight and ten morbidly obese (greater than 90 percent ideal body weight) age-matched female subjects. No significant difference between normal and obese subjects was found in ranitidine peak serum concentration, volume of distribution, clearance, and elimination rate constant. Ranitidine volume of distribution and clearance were significantly smaller in the obese subjects per kilogram of total body weight (1.45 vs. 0.80 L/kg and 0.59 vs. 0.33 L/h/kg, respectively; p less than 0.001) but not when normalized to ideal body weight (1.65 vs. 1.45 L/kg and 0.68 vs. 0.59 L/h/kg). We conclude that obese patients receiving ranitidine therapy should be treated with standard dosages or dosages based on ideal body weight.
在10名体重正常和10名病态肥胖（超过理想体重的90%）且年龄匹配的女性受试者中测定了静脉注射50毫克雷尼替丁单次剂量的药代动力学。在雷尼替丁的血清峰值浓度、分布容积、清除率和消除速率常数方面，正常受试者和肥胖受试者之间未发现显著差异。按每千克总体重计算，肥胖受试者的雷尼替丁分布容积和清除率显著较小（分别为1.45 vs. 0.80升/千克和0.59 vs. 0.33升/小时/千克；p<0.001），但按理想体重归一化后则无显著差异（1.65 vs. 1.45升/千克和0.68 vs. 0.59升/小时/千克）。我们得出结论，接受雷尼替丁治疗的肥胖患者应以标准剂量或基于理想体重的剂量进行治疗。
